{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T06:04:40Z","timestamp":1770012280185,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H22-kanen-wakate-016"],"award-info":[{"award-number":["H22-kanen-wakate-016"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18fk0210021"],"award-info":[{"award-number":["JP18fk0210021"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.antiviral.2018.08.008","type":"journal-article","created":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T22:24:10Z","timestamp":1534285450000},"page":"161-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones"],"prefix":"10.1016","volume":"158","author":[{"given":"Asako","family":"Murayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norie","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Shiina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussein Hassan","family":"Aly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamichi","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaji","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanobu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.08.008_bib1","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.1128\/JVI.00253-11","article-title":"Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052","volume":"85","author":"Fridell","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.08.008_bib2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.08.008_bib3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.coph.2016.07.014","article-title":"HCV NS5A replication complex inhibitors","volume":"30","author":"Gao","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.08.008_bib4","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1053\/j.gastro.2017.12.015","article-title":"Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1-7 and escape variants","volume":"154","author":"Gottwein","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2018.08.008_bib5","first-page":"549","article-title":"Odalasvir","volume":"42","author":"Kanda","year":"2017","journal-title":"Drugs Future."},{"key":"10.1016\/j.antiviral.2018.08.008_bib6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2012.11.012","article-title":"Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir","volume":"58","author":"Karino","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2018.08.008_bib7","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1038\/nprot.2006.395","article-title":"Cell culture and infection system for hepatitis C virus","volume":"1","author":"Kato","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.antiviral.2018.08.008_bib8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/jmv.1055","article-title":"Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient","volume":"64","author":"Kato","year":"2001","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.08.008_bib9","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"Kumada","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2018.08.008_bib10","first-page":"E1101","article-title":"Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains","volume":"109","author":"Li","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2018.08.008_bib11","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"Lok","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.08.008_bib12","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1128\/JVI.02929-13","article-title":"A novel strategy to develop a robust infectious hepatitis C virus cell culture system directly from a clinical isolate","volume":"88","author":"Lu","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.08.008_bib13","doi-asserted-by":"crossref","first-page":"8030","DOI":"10.1128\/JVI.02088-06","article-title":"The NS3 helicase and NS5B-to-3'X regions are important for efficient hepatitis C virus strain JFH-1 replication in Huh7 cells","volume":"81","author":"Murayama","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.08.008_bib14","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1128\/JVI.05386-11","article-title":"Production of infectious chimeric hepatitis C virus genotype 2b harboring minimal regions of JFH-1","volume":"86","author":"Murayama","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.08.008_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02124-16","article-title":"Amino acid mutations in the NS4A region of hepatitis C virus contribute to viral replication and infectious virus production","volume":"91","author":"Murayama","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.08.008_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00273-16","article-title":"Completion of the entire hepatitis C virus life cycle in vero cells derived from monkey kidney","volume":"7","author":"Murayama","year":"2016","journal-title":"mBio"},{"key":"10.1016\/j.antiviral.2018.08.008_bib17","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1128\/JCM.00487-12","article-title":"Japanese reference panel of blood specimens for evaluation of hepatitis C virus RNA and core antigen quantitative assays","volume":"50","author":"Murayama","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2018.08.008_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000885","article-title":"RNA polymerase activity and specific RNA structure are required for efficient HCV replication in cultured cells","volume":"6","author":"Murayama","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.08.008_bib19","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.3748\/wjg.v20.i11.2902","article-title":"Hepatitis C virus NS5A inhibitors and drug resistance mutations","volume":"20","author":"Nakamoto","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2018.08.008_bib20","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.bbrc.2011.05.144","article-title":"Development of recombinant hepatitis C virus with NS5A from strains of genotypes 1 and 2","volume":"410","author":"Okamoto","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2018.08.008_bib21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2013.03.030","article-title":"NS5A inhibitors in the treatment of hepatitis C","volume":"59","author":"Pawlotsky","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2018.08.008_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004064","article-title":"A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity","volume":"10","author":"Qi","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.08.008_bib23","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1053\/j.gastro.2010.11.036","article-title":"Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-alpha","volume":"140","author":"Scheel","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2018.08.008_bib24","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1017\/S0950268814000478","article-title":"Changes in hepatitis C virus genotype distribution in Japan","volume":"142","author":"Toyoda","year":"2014","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.antiviral.2018.08.008_bib25","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2018.08.008_bib26","doi-asserted-by":"crossref","first-page":"S487","DOI":"10.1016\/S0168-8278(13)61200-3","article-title":"Findings from clinical virology studies on ACH-3102 are consistent with preclinical observations on its improved potency against genotype-1a HCV and resistant variants","volume":"58","author":"Yang","year":"2013","journal-title":"J. Hepatol."},{"issue":"Suppl. 2","key":"10.1016\/j.antiviral.2018.08.008_bib27","doi-asserted-by":"crossref","first-page":"S330","DOI":"10.1016\/S0168-8278(12)60857-5","article-title":"Preclinical Characteristics of ACH-3102: a novel HCV NS5A inhibitor with improved potency against genotype-1a virus and variants resistant to 1st generation NS5A inhibitors","volume":"56","author":"Yang","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2018.08.008_bib28","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2018.08.008_bib29","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.1073\/pnas.0503596102","article-title":"Robust hepatitis C virus infection in vitro","volume":"102","author":"Zhong","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218303097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218303097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:29:06Z","timestamp":1759062546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218303097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":29,"alternative-id":["S0166354218303097"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.08.008","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}